EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biopharmaceutical Characterization of Grapiprant Within the BCS Framework Under Canine-Relevant Conditions: Solubility and Caco-2 Permeability Assessment

Zeyu Wen iD, Xilu Sun, Sumeng Chen, Jinyan Meng, Runlin Yu, Shuyan Guo, Xingyuan Cao iD

Pharmaceutics · 15.08.2026 · 18 (8) · 1010

DOI: 10.3390/pharmaceutics18081010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 15.08.2026. Verfasst von Zeyu Wen und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, China Agricultural University, Beijing 100193, China. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: QX001.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Biopharmaceutics Classification System (BCS) classifies drug substances according to their aqueous solubility and intestinal permeability; however, its application to veterinary drugs should account for species-specific gastrointestinal physiology. Grapiprant is a selective prostaglandin E2 receptor subtype 4 (EP4) antagonist approved as an oral tablet to control pain and inflammation associated with osteoarthritis in dogs, but its properties within the BCS framework remain unclear.

Methods

This study evaluated the equilibrium solubility of grapiprant across pH conditions relevant to the canine gastrointestinal tract and calculated the dose number (D0) based on different gastric fluid volumes. A Caco-2 cell monolayer model was used to assess grapiprant intestinal permeability and the effects of time, concentration, pH, and efflux transporter inhibitors on its transepithelial transport.

Results

Grapiprant showed relatively small changes in solubility across the tested pH range. D0 varied with pH and gastric fluid volume and approached or fell below 1 at larger fluid volumes. In the Caco-2 model, grapiprant showed generally limited apparent absorptive permeability, with permeability varying with pH. Efflux ratios were greater than 1, and verapamil reduced the efflux ratio, suggesting possible P-glycoprotein (P-gp) involvement.

Conclusions

These findings suggest that both solubility and apparent intestinal permeability may limit the oral absorption of grapiprant under certain canine-relevant conditions. Accordingly, this study provides a biopharmaceutical characterization of grapiprant within the BCS framework rather than a definitive canine BCS classification, highlighting the importance of considering canine gastrointestinal conditions when interpreting its solubility and permeability. The results may support future optimization of dosing conditions and oral formulations.

Schlagwörter

Stichwörter der Autor:innen

Caco-2 cell monolayer modelbiopharmaceutical propertiesgrapiprantpermeabilitysolubility

Autor:innen und Institutionen

  • College of Veterinary Medicine, China Agricultural University, Beijing 100193, China.
  • National Center for Veterinary Drug Safety Evaluation GCP Laboratory, Beijing 100193, China.

ORCID-Profile: Zeyu Wen, Xingyuan Cao

Förderung

  • QX001

Zitieren

APA

Wen, Z., Sun, X., Chen, S., Meng, J., Yu, R., Guo, S., & Cao, X. (2026). Biopharmaceutical Characterization of Grapiprant Within the BCS Framework Under Canine-Relevant Conditions: Solubility and Caco-2 Permeability Assessment. Pharmaceutics, 18(8), 1010. https://doi.org/10.3390/pharmaceutics18081010

Vancouver

Wen Z, Sun X, Chen S, Meng J, Yu R, Guo S, et al. Biopharmaceutical Characterization of Grapiprant Within the BCS Framework Under Canine-Relevant Conditions: Solubility and Caco-2 Permeability Assessment. Pharmaceutics. 2026;18(8):1010. doi:10.3390/pharmaceutics18081010

BibTeX
@article{Wen2026,
  author = {Wen, Zeyu and Sun, Xilu and Chen, Sumeng and Meng, Jinyan and Yu, Runlin and Guo, Shuyan and Cao, Xingyuan},
  title = {Biopharmaceutical Characterization of Grapiprant Within the BCS Framework Under Canine-Relevant Conditions: Solubility and Caco-2 Permeability Assessment},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1010},
  doi = {10.3390/pharmaceutics18081010}
}
Kostenlos starten →